



Our Mission

At Osprey Medical, our mission is to improve outcomes in patients with Chronic Kidney Disease (CKD) by reducing Contrast Induced Acute Kidney Injury (CI-AKI) and lowering hospital costs. Osprey's proprietary technologies reduce the amount of contrast (dye) injected into patients during heart catheterization procedures without compromising X-ray image quality for the physician.

A Global Leader in Dye Minimization Technologies

Osprey maintains a valuable, patent protected and innovative product portfolio with FDA-cleared, TGA-cleared and CE-Marked products. Our lead technology platform, DyeVertTM is the only device with an FDA cleared claim for contrast dye reduction without compromised image quality for patients undergoing angiography procedures. This disposable device showed solid volume growth of 57% to 7,200 units in FY2018 representing a three-year Compound Annual Growth Rate (CAGR) of 179%, driven by new user accounts, solid growth in Group Purchasing Organization (GPO) accounts and deeper penetration within hospital accounts. The addressable market is US\$1.65bn annually.

A Significant Burden of Illness

Approximately 25% of all angiography patients are at risk of CI-AKI, a frequent and dangerous complication for patients and expensive for hospitals to manage¹. AKI is a growing problem for hospitals, with a 19.4x increase in the risk of death, 4.6x increase in the risk of bleeding and 1.8x increased risk of a heart attack¹. The cost of CI-AKI to hospitals each year is approximately US\$1.7bn due to increased length of stay, 30-day re-admissions and reimbursement penalties². There is growing evidence that shows compelling reduction ranging from 25-63% in CI-AKI rates associated with prevention strategies that include hydration protocols and dye reduction using DyeVert.




SNAPSHOT

ASX Ticker	OSP
GICS¹ Code	3510
Sector	Healthcare Equipment & Services
Share Price	A\$0.11 (as at 11 June 2019)
52 Week High / Low	A\$0.255 / A\$0.085
Market Capitalization	A\$45.0 / US\$31.5 million
Cash (as at 31 Mar 2019)	US\$25.3 million (no debt)
Enterprise Value	A\$8.9 / US\$6.2 million
Top 20 CDI² Holders	84.8%

¹ GICS – Global Industry Classification Standard; ² CDI – CHESS Depository Interest; Assumes AUD/USD = 0.70

QUARTERLY UNIT VOLUMES SINCE LAUNCH



BOARD OF DIRECTORS

John Erb	Non-Executive Chairman
Mike McCormick	President & CEO
Andy Jane	Non-Executive Director
Neville Mitchell	Non-Executive Director
Sandra Lesenfants	Non-Executive Director
Chris Nave	Non-Executive Director


¹ Tsai, et al. JACC Intv 2014;7:1-9

² Prasad, et al. ACC 2019 abstract;

Execution of GPO Strategy – Four Contracts Signed

We introduced our National Accounts or Group Purchasing Organisation (GPO) Strategy approximately 12 months ago, and since that time we have made significant progress in executing our plan. GPOs represent some of the largest networks of hospitals and health care providers in the US and have some of the largest global healthcare databases.

Osprey has struck agreements with four major GPOs to date, providing 50% market coverage of AKI in the US market. This includes a contract with Premier, Inc. (NASDAQ:PINC) following the award of Technology Breakthrough for DyeVert in November 2018. This provides access for Osprey to Premier's ~4,000 hospitals. GPO based sales were up 158% in FY2019.



We have significant headroom to grow, based on low penetration rates of contracted GPO hospitals in existing sales territories. Our field sales force and clinical support staff are focused on hospitals within GPOs, working with hospitals and doctors to standardize care, both to improve AKI outcomes and lower hospital cost. This leads to adoption based on a standard care-pathway protocol for all member hospitals.

Osprey will continue to make investments in GPO-supported studies to build GPO-level relationships and support adoption in member hospitals and build AKI awareness.

Registry to Generate Real-World Clinical Evidence


In May 2019, Osprey launched the DyeMINISH™; a global patient registry to evaluate the ongoing safety and performance of the DyeVert Contrast Reduction System

DyeMINISH™
Registry

during standard clinical use in a real-world patient population. The first patient in the study was enrolled in May. The DyeMINISH registry is a retrospective, large-scale, multi-centre study designed to enrol up to 10,000 participants and is expected to complete in late 2023. The study will provide critical real-world evidence, which is important for healthcare and regulatory decision making, policy development, clinical guidelines and payor coverage; support peer-reviewed publications and education/awareness build-out and improves clinical care for CKD patients undergoing angiography procedures.

US\$1.65 Billion Market

<1% penetration



Product Innovation and Future Milestones

Osprey's R&D activities continue to deliver innovative new products. A recent example was the successful launch of our DyeVert™ Plus EZ product in November 2018. This very simple yet innovative user interface reduces set-up time in the angiography suite from minutes to seconds. Clinician acceptance to date has been strong, with approximately 60% of our unit volume mix attributable to DyeVert Plus EZ in the first full quarter post launch, which continues to grow.

Our ability to innovate according to clinician requirements has underpinned our strong growth trajectory, with 18 consecutive quarters of growth to date.

Additionally, Osprey continues to work towards securing FDA clearance of a new DyeVert product that can be used to minimize contrast volume with power injectors. If successful, it represents a new market opportunity for the Company. Osprey also expects to sign new agreements with at least one Group Purchasing Organisation in 2019, thereby significantly expanding our reach into new hospital accounts. We also anticipate formal market launches into the UK and Italy and continued awareness building through new scientific studies validating the use of DyeVert.

CONTACT INFORMATION

HEAD OFFICE

5600 Rowland Road
Suite 250
Minnetonka, MN 55343
T: +1 952 955 8230

INVESTOR RELATIONS

Dr Thomas Duthy
T: +61 402 493 727
E: tduthy@ospreymed.com

OSPREY™
MEDICAL